

Article

Three-dimensional biofabrication models of endometriosis and the endometriotic microenvironment

Jillian R. H. Wendel ¹, Xiyin Wang ¹, Lester J. Smith ^{2,3} and Shannon M. Hawkins ^{1,4,5*}

¹ Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN 46202, USA; jhufgard@iu.edu, xw49@iu.edu

² Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN 46202, USA;

³ 3D Bioprinting Core, Indiana University School of Medicine, Indianapolis, IN 46202, USA; smitlej@iu.edu

⁴ Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA;

⁵ Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA;

* Correspondence: shhawkin@iu.edu; Tel.: +1-317-274-8225

Abstract: Endometriosis occurs when endometrial-like tissue grows outside the uterine cavity, leading to pelvic pain, infertility, and increased risk of ovarian cancer. The present study describes the optimization and characterization of cellular spheroids as building blocks for Kenzan scaffold-free method biofabrication and proof-of-concept models of endometriosis and the endometriotic microenvironment. The spheroid building blocks must be a specific diameter (~500 μ m), compact, round, and smooth to withstand Kenzan biofabrication. Under optimized spheroid conditions for biofabrication, the endometriotic epithelial-like cell line, 12Z, expressed high levels of estrogen-related genes and secreted high amounts of endometriotic inflammatory factors that were independent of TNF α stimulation. Heterotypic spheroids, composed of 12Z and T-HESC, an immortalized endometrial stromal cell line, self-assembled into a biologically relevant pattern, consisting of epithelial cells on the outside of the spheroids and stromal cells in the core. 12Z spheroids were biofabricated into large three-dimensional constructs alone, with HEYA8 spheroids, or as heterotypic spheroids with T-HESC. These three-dimensional biofabricated constructs containing multiple monotypic or heterotypic spheroids represent the first scaffold-free biofabricated *in vitro* models of endometriosis and the endometriotic microenvironment. These efficient and innovative models will allow us to study the complex interactions of multiple cell types within a biologically relevant microenvironment.

Keywords: endometriosis, 12Z, spheroid, biofabrication, scaffold-free, Kenzan

1. Introduction

Endometriosis is a common disease affecting 178-200 million women and girls worldwide [1-3]. Endometriosis occurs when endometrial-like tissue grows outside the uterine cavity, frequently invading structures within the pelvic cavity, including the peritoneum, ovaries, bladder, small intestine, or colon. Women with endometriosis can exhibit debilitating chronic pelvic pain and infertility [1-3]. Endometriosis often results in decreased quality of life, as measured by the

Endometriosis Health Profile-30 (EHP-30) [4-8]. Women with endometriosis have higher hospital admissions rates, increased work and school day absences, and increased economic burden [9-11]. Women with endometriosis are also at a significantly increased risk for developing ovarian cancer, specifically the endometriosis-associated ovarian cancers, including clear cell or endometrioid ovarian adenocarcinoma [12-15].

The scarcity of representative endometriotic *in vitro* models hinders research within the endometriosis field [16-19]. Immortalized stromal cell lines have been developed from endometrial tissue from women with endometriosis or endometriotic lesions [20,21]. However, few immortalized epithelial endometriotic cell lines exist, with 12Z cells being the most studied [16,21,22]. While traditional monolayer culture has set the groundwork for many advancements, limitations are seen in its inability to recapitulate therapeutic outcomes *in vivo* [23]. These limitations may be due to the lack of reflection of the complete and complex three-dimensional (3D) interactions and their surrounding microenvironment [17]. For example, 3D models better recapitulate the highly inflammatory microenvironment of endometriosis compared to monolayer [24]. Additionally, 3D models of ovarian cancer better represent human tissue characteristics, gene expression patterns, and chemotherapy response [24-28]. However, for *in vitro* models to better represent endometriosis and the endometriotic microenvironment, continued advancement is required.

In the present study, we describe a method of culturing spheroids (~500 μm) that retain endometriotic characteristics. Additionally, we provide proof-of-concept models of complex 3D biofabricated tissue-like constructs using the scaffold-free Kenzan method [29] to assemble spheroids into larger constructs. This body of work is intended as a proof-of-concept foundation to use these modalities to study endometriosis and the endometriotic microenvironment.

2. Experimental Section

2.1. Biofabrication Equipment and the Kenzan Method

The Regenova Bio 3D Printer (Cyfuse Biomedical K.K., Tokyo, Japan), a semi-automated biofabrication robot, was used in two distinct ways for the scope of this work. First, the Regenova Bio 3D Printer used a vision system to examine spheroids and assess roundness, surface smoothness, and diameter [29-31]. This assessment was used to optimize spheroid parameters before biofabrication because the Kenzan method requires a specific set of characteristics for successful biofabrication. Secondly, the Regenova Bio 3D Printer used spheroids as building blocks for 3D biofabrication using the Kenzan method. The Kenzan method of biofabrication is conceptualized from the Japanese Ikebana method of flower arranging. In the Japanese form of flower arranging, a kenzan is a metal needle array used to hold floral arrangements in place (Figure 1A). In the Kenzan method of biofabrication, the Kenzan is the microneedle array (Figure 1B) used to hold cell spheroids [29-31] in contact with one another so they can fuse to form larger, more sophisticated tissue constructs. The Kenzan (Amuza, Inc., San Diego, CA) used was a 9 x 9 microneedle array made from stainless steel and housed in a biocompatible casing containing phosphate buffered saline. The Regenova Bio 3D Printer interfaced with the Bio 3D Designer software (Cyfuse) to delineate the user-defined construct design. The robotic arm of the Regenova lifted the spheroids from the 96-well plate, using a vacuum nozzle (Amuza, Inc.), and placed each spheroid on the Kenzan, in a user-defined pattern. The Kenzan containing the biofabricated spheroids were transferred to a culture dish containing media and incubated in a humidified incubator at 37°C and 5% CO₂, allowing the spheroids to fuse into a larger tissue construct. The construct was removed from the Kenzan, leaving behind an utterly scaffold-free construct [29] comprised only of cells and their self-secreted extra-cellular matrix (Figure 1C). The parameters used are reported below.




Figure 1. Kenzan method of biofabrication. **A)** A kenzan (Ansel Adams Museum, Yosemite National Park, CA) used for flower arranging. Needles (white arrow) would hold the floral stems in place. **B)** A Kenzan used for 3D biofabrication with the Regenova Bio 3D Printer. This Kenzan is made of a 9 x 9 stainless steel needle array (black arrow) and supported by two platens (arrowhead) to hold the needles in alignment and aid in removing the construct. **C)** Workflow of Kenzan method biofabrication. Step 1 – Generation of building blocks for biofabrication, called spheroids, large (~500 μ m), tight, dense masses of cells that do not break up with gentle disruption. Step 2 – Spheroids are placed onto the needles of the Kenzan with a robotic arm's assistance. The X, Y, and Z placement on Kenzan is user-defined, allowing for a wide range of construct designs. Step 3 – Spheroids are incubated in media on the Kenzan, allowing for a naturally secreted extracellular matrix to fuse adjacent spheroids. Step 4 – The Kenzan is gently removed with one of the two platens' aid, leaving behind a scaffold-free construct.

2.2. Cell Lines

12Z cells, an SV40-transformed endometriotic epithelial-like cell line derived from red peritoneal endometriosis lesions [21], was obtained from Asgi Fazleabas, Ph.D. (Michigan State University College of Human Medicine, Grand Rapids, MI) with written permission from Anna Starzinski-Powitz, Ph.D. (Wolfgang Goethe Frankfurt University, Germany). 12Z cells were maintained in Dulbecco's Modified Eagle Media (DMEM)/F12 (Thermo Fisher Scientific, Waltham, MA), supplemented with 10% fetal bovine serum (Atlanta Biologicals, Minneapolis, MN or Corning Inc, Corning, NY) and 1% penicillin/streptomycin (Thermo Fisher Scientific). HEYA8, an epithelial ovarian cancer cell line [32], was obtained from the Cytogenetics and Cell Authentication Core at the University of Texas MD Anderson Cancer Center (Houston, TX). HEYA8 cells were maintained in RPMI (Thermo Fisher Scientific), supplemented with 10% fetal bovine serum (Atlanta Biologicals or Corning) and 1% penicillin/streptomycin. T-HESC, a human telomerase-transformed endometrial stromal cell line [33], was obtained through American Type Culture Collection (ATCC) (Manassas, VA, CRL-4003). T-HESCs were maintained in DMEM/F12 without phenol red (Thermo Fisher Scientific), supplemented with 10% fetal bovine serum (Atlanta Biologicals), 1% Corning ITSTM+ Premix Universal Culture Supplement [insulin (5 μ g/ mL), transferrin (5 μ g/ mL), and selenious acid (5 ng/ mL) (Thermo Fisher Scientific)], and 500 ng/mL puromycin (Thermo Fisher Scientific).

HEK293T, an adenovirus type 5 DNA-transformed human embryonic kidney cell line [34], was obtained through American Type Culture Collection (ATCC, CRL-3216). HEK293T cells were maintained in DMEM (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (Atlanta Biologicals) and 1% penicillin/streptomycin. All cell lines were maintained in a humidified incubator at 37°C and 5% CO₂. Cell line authentication was confirmed using CellCheck 9 Plus (IDEXX BioAnalytics, Westbrook, ME). All cell lines were negative for mycoplasma contamination (MycoAlert Plus Mycoplasma Detection Kit, Lonza, Switzerland).

2.3. Fluorescent Labeling of Live Cells

12Z cells were transfected with a Td-tomato marker. The tdTomato-C1 plasmid was a gift from Michael Davidson (Addgene plasmid #54653: <http://n2t.net/addgene:54653>; RRID: Addgene_54653). One day before transfection, 500,000 12Z cells per well were seeded in a 6-well plate. Lipid-based transfection (Lipofectamine® 2000, Thermo Fisher Scientific) was carried out per manufacturer's instructions, using 2.5 µg DNA in triplicate. The following day cells were trypsinized, and triplicates were pooled and reseeded to three 10-cm dishes at 4,000,000 cells per plate. Cells were selected in 300 µg/mL of geneticin (Thermo Fisher Scientific). Fluorescent expression was confirmed on an EVOS FL Cell Imaging System (Thermo Fisher Scientific) using the EVOS RFP light cube (Thermo Fisher Scientific, excitation: 531/40 nm and emission: 593/40 nm).

HEYA8 and T-HESC cells were transduced to express a green fluorescent protein (GFP). Lentiviral shRNA particles were generated using HEK293T cells. HEK293T cells were seeded at 500,000 cells per well. Lipid-based transfection (Lipofectamine® 2000) was carried out per the manufacturer's instructions. The GIPZ non-silencing control plasmid containing GFP was obtained from the Core Based Assay Screening Service (C-BASS) Core of Baylor College of Medicine. The lentiviral packaging mix (Rev1b, Tat1b, HGP42, and VSVG) was mixed with the lipid media and added to the HEK293T cells, gently swirled, and incubated [35]. Media was changed at 24 hours, and viral particles were collected at 48 and 72 hours by removing media and spinning at 4°C at 800 x g for 10 minutes. For transduction, 150,000 HEY8 cells/well or 500,000 T-HESC cells/well were seeded. Transduction occurred via centrifugation with 5 µg/ml of polybrene (Sigma, St. Louis, MO) at 800 x g for 60 min at room temperature followed by six hours of incubation. A volume of 0.5 mL of cell media was added to the cells and incubated overnight. The following day, media was replaced with fresh media. On day five post-transduction, HEY8 cell media was supplemented with 1 µg/mL puromycin for selection. HEY8 cells were maintained under selective pressure for two weeks. Fluorescence was confirmed on an EVOS FL Cell Imaging System using the EVOS GFP light cube (Thermo Fisher Scientific, excitation: 470/22 nm and emission: 525/50 nm). On day three post-transduction, T-HESC cells were seeded as a single cell per well. Fluorescence was confirmed, and the brightest colonies were expanded.

2.4. Optimization of Spheroids for Kenzan Biofabrication

Cell density, time in culture, and serum effects were assessed to determine the best conditions for spheroids for Kenzan biofabrication. For 3D biofabrication, we classified spheroids as optimal if they met the criteria of 80-100 roundness (%), 0-5 smoothness (%), and 450-650 diameter (µm). Cells were seeded in PrimeSurface® 3D Culture Spheroid plates: Ultra-low Attachment Plates (S-Bio, Hudson, NH) and allowed to aggregate into spheroids over the course of up to 120 hours. Spheroids were scanned using the Regenova Bio 3D Printer vision system daily for up to 5 consecutive days to assess roundness, smoothness, and diameter [30]. Biologically, we classified masses of cells as "spheroids" if gentle disruption by pipetting failed to break up the tight, dense mass.

2.5. Scaffold-free 3D Biofabrication Optimization

Data and tissue-like 3D biofabricated constructs were acquired at the 3D BioPrinting Core. Spheroids were 3D biofabricated onto a Kenzan in a user-defined 3D design (shown below) using the

Regenova Bio 3D Printer [29,31]. Briefly, spheroids in 96-well ultra-low attachment round-bottom plates (S-Bio) were digitally scanned for roundness, smoothness, and diameter. If 80-100 roundness (%), 0-5 smoothness (%), and 450-650 diameter (μm) were met, the spheroid was picked up via 2 kPa of suction with a 26-gauge nozzle (Amuza, Inc.) and placed on the Kenzan via the robotic arm. Following biofabrication, spheroids on the Kenzan were incubated in media in a humidified incubator at 37°C and 5% CO₂ for 48-72 hours. Constructs were removed from the Kenzan and incubated. To prevent adhesion to culture dishes, constructs were incubated in ultra-low attachment 12-well plates (Sigma).

2.6. Fixation of Spheroids and Constructs

Spheroids (five days post-seeding) or constructs (24 hours after removal from the Kenzan) were collected, washed with 1X phosphate-buffered saline (PBS), fixed in 1% paraformaldehyde (Thermo Fisher Scientific) prepared in 1X PBS for 30 minutes at 4°C, and washed in 1X PBS, followed by 0.85% sodium chloride in 1X PBS, and 0.85% sodium chloride in 70% ethanol for 30 minutes apiece at room temperature with gentle agitation. Spheroids and constructs were stored in 70% ethanol until embedding. For embedding, spheroids were placed at the bottom of a 15 mL tube, and 20 μL of pre-warmed HistoGel (Thermo Fisher Scientific) was added. The gel was allowed to solidify for 20 minutes at 4°C. The plug was then removed, rinsed in 70% ethanol, and stored in 70% ethanol. Plugs and constructs were transferred to the Histology Core of the Indiana Center for Musculoskeletal Health at IU School of Medicine for processing, paraffin embedding, and 5 μm sectioning.

2.7. Immunofluorescent Staining

Paraffin was dissolved from 5 μm sectioned tissues, and tissue was rehydrated by a series of washes 3 minutes each: xylene, xylene, 1:1 xylene/100% ethanol, 100% ethanol, 100% ethanol, 95% ethanol, 70% ethanol, 50% ethanol, and five minutes in water. Heat-mediated antigen retrieval was performed by submerging slides in pre-warmed citrate buffer, pH 6.0 (Vector Laboratories, Burlingame, CA) for three minutes on high in a pressure cooker (Nesco, Two Rivers, WI) followed by four minutes on warm. Slides were allowed to cool to room temperature before being washed with gentle agitation for three minutes each: water, Tris-Buffered Saline (TBS), and TBS with 0.1% Tween 20 (TBS-T) (Thermo Fisher Scientific). Sections were permeabilized for nuclear detection via 0.4% Triton X-100 (Sigma) in 1X TBS for 10 minutes with gentle rocking followed by three TBS-T washes for three minutes each. Sections were blocked with 5% normal donkey serum (Jackson ImmunoResearch Laboratories, INC., West Grove, PA) for one hour at room temperature in a humidified chamber. Sections were then washed with TBS-T three times for three minutes each with gentle rocking. Staining was completed on 4 independent spheroids for proliferation and apoptosis markers. Primary antibodies [Ki-67 (Millipore Sigma, AB9260, 1:50) and cleaved caspase 3 (cCAS3, Cell Signaling Technology, Danvers, MA, 9661S, 1:100)] were diluted in 1% normal donkey serum. Sections were incubated overnight at 4°C in a humidified chamber with the primary antibody. Slides were washed three times with TBS-T for three minutes with gentle rocking. The secondary antibody was diluted in 1% normal donkey serum (Donkey anti-Rabbit 555, Thermo Fisher Scientific, A31572, 1:100), and sections were incubated at room temperature for 2 hours. Sections were then washed three times with TBS-T for three minutes with gentle rocking. The sections were mounted with Fluoromount-G mounting media with 4',6-diamidino-2-phenylindole (DAPI, Thermo Fisher Scientific). Secondary only stained sections were used as a negative control. Immunofluorescent staining was imaged on an EVOS FL Cell Imaging System.

2.8. Immunohistochemical Staining

Section preparation methods for immunohistochemical staining of biofabricated constructs were similar to immunofluorescent staining of spheroids. Briefly, 5 μm sections were deparaffinized and rehydrated using a graded alcohol series. Rehydration was followed by heat-mediated antigen

retrieval in citrate buffer, permeabilization in 0.4% Triton X-100, and quenching with 3% hydrogen peroxide (Thermo Fisher Scientific) in methanol (Thermo Fisher Scientific). Sections were blocked in 5% normal goat serum (Vector Laboratories) for 1 hour. Sections were then washed with TBS-T three times for three minutes each with gentle rocking. Sections were incubated overnight with the primary antibody in a humidified chamber at 4°C. Primary antibodies were diluted in 1% normal goat serum. Cytokeratin 7 (KRT7, Abcam, United Kingdom, Ab181598, 1:100) and membrane metalloendopeptidase (CD10, Abcam, Ab208778, 1:2000) were used. Sections were washed and incubated at room temperature for one hour with goat-anti-rabbit horseradish peroxidase-conjugated secondary antibody (2 µg/mL, Vector Laboratories). Immunoreactivity was detected using the VECTASTAIN Elite ABC-Peroxidase Kit (Vector Laboratories) and the DAB Substrate Kit (Vector Laboratories) following the manufacturer's instructions. Sections were then counterstained by incubating in hematoxylin (Sigma) for one min, rinsed in water, dipped in 0.025% hydrochloric acid (Thermo Fisher Scientific), rinsed in water, dipped in saturated lithium carbonate (Thermo Fisher Scientific) until nuclei turned blue, and then washed in water for five minutes with gentle agitation. Dehydration of sections was done by graded alcohol series: 50% ethanol for five minutes, 70% ethanol for 5 minutes, 80% ethanol for five minutes, 95% ethanol for 5 minutes, 100% ethanol for 10 minutes two times, and xylene for 10 minutes two times. Following dehydration, sections were mounted using mounting media (Thermo Fisher Scientific). Immunohistochemical staining was imaged on a Zeiss Axio Lab.A1 microscope (Oberkochen, Germany).

2.9. Secreted Inflammatory Cytokines Assessment

Monolayer cells were seeded 24 hours, and spheroids were seeded 72 hours before tumor necrosis factor-alpha (TNF α) stimulation. Both monolayer and spheroids were seeded with 10,000 cells. The media was replaced with serum-free media containing 15 ng/mL TNF α (Sigma) or an equal volume of dimethyl sulfoxide (DMSO, Thermo Fisher Scientific). Cells in monolayer and spheroid were incubated for 24 hours before conditioned media collection. Conditioned media was collected and diluted 1:4, based on optimization (data not shown), with serum-free media and delivered to the Multiplex Analysis Core at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center for analysis. Interleukin (IL)-6, IL-8, and monocyte chemotactic protein-1 (MCP1) were examined using the Human Cell Culture Supernatant 3-Plex Human Adipocyte Magnetic Bead Panel (HADCYMAG-61K, EMD Millipore, Burlington, MA) following manufacturer's instructions on the BioPlex 200 System (Bio-Rad, Hercules, CA). A standard curve was generated based on the manufacturer's instructions, and the kit supplied standards were used to determine the pg/mL of samples. Technical replicates were run in duplicate with 3-4 biological replicates.

2.10. RNA Extraction and qRT-PCR

In an independent experiment, wells were seeded with 20,000 cells per well for both monolayer and spheroid groups. RNA was extracted using the TaqMan MicroRNA Cells-to-CT Kit (Thermo Fisher Scientific) following the manufacturer's instructions. A NanoDrop ND-1000 (Thermo Scientific) was used for nucleic acid quantification, and 1000 ng of RNA was reverse transcribed in a 20 µL reaction using 50 units of MultiScribe™ Reverse Transcriptase (RT, Thermo Fisher Scientific), 1X RT Buffer (Thermo Fisher Scientific), 5 mM deoxynucleoside triphosphate (Thermo Fisher Scientific), 2.5 µM random hexamers (Thermo Fisher Scientific), and 6 units of RNase inhibitor (Thermo Fisher Scientific). cDNA was generated in a 2720 Thermal Cycler (Thermo Fisher Scientific) with the following conditions: 10 minutes at 25 °C, 30 minutes at 48 °C, and 5 minutes at 95 °C. Samples were diluted to 100 µL and used for quantitative PCR (qPCR). Real-time qPCR (qRT-PCR) was performed using either previously published SYBR green primers [β -Actin; cytochrome p450, family 19a1 (CYP19A1); or hydroxysteroid 17-beta dehydrogenase1 (HSD17 β 1) [36]] or predesigned TaqMan Gene Expression Assays [Thermo Fisher Scientific, estrogen receptor type 1 (ESR1) (Hs01046818_m1)]. β -Actin was used as an endogenous control. TaqMan PCR was performed using TaqMan Universal PCR Master Mix II, No UNG (Thermo Fisher Scientific). SYBR Green PCR was

performed using SYBR Green PCR Master Mix (Thermo Fisher Scientific). Reaction conditions followed the recommendations on the QuantStudio3 Real-Time PCR System (Thermo Fisher Scientific). Each sample was run in duplicate, and a non-template control (nuclease-free water) was included in each plate. All SYBR green runs had dissociation curves to identify potential primer-dimers. Relative quantification was determined using $2^{-\Delta\Delta CT}$ [37]. One sample was excluded for being two standard deviations from the average, leaving 3-6 biological replicates per group.

2.11. Statistical Analysis

Statistical analyses were conducted through the InStat package for Prism8 (GraphPad, San Diego, CA). Comparisons of two groups were performed using a two-sided Student's *t*-test. A 2-way ANOVA was used with Tukey's multiple comparison test when more than two groups were present. Analysis of both treatment and gene/protein was performed using a 2-way ANOVA with a Šidák's correction for multiple comparisons across treatment [38]. Data were presented as the mean and standard error of the mean. Significant differences between groups were determined by $P < 0.05$.

3. Results

3.1. 12Z Cells Grow as Large Spheroids within Parameters of Biofabrication by the Kenzan Method

The goal of this project was to 3D biofabricate endometriosis and endometriotic microenvironment models using the Kenzan method. The first step of this process involved the production of spheroids within appropriate parameters for biofabrication on Kenzan. Based on spheroids successfully biofabricated in the past [30], optimal goal parameters for successful biofabrication were 80-100 roundness (%), 0-5 smoothness (%), and 450-650 diameter (μm). We started with 12Z cells because 1) 12Z cells were derived from a red peritoneal endometriosis lesion and transformed using SV40 T-antigen [21], allowing for a replenishable supply of cells; 2) the 12Z cells are commercially available (<https://www.abmgood.com/immortalized-human-endometriotic-cell-line-12z.html>) and have a reasonable doubling time [21] for efficient use in real-time experiments; 3) 12Z cells exhibit epithelial-like properties both in cytokeratin expression and morphology [21]; 4) 12Z cells exhibit high expression of prostaglandin E2, matrix metalloproteinase, estrogen and progesterone biosynthesis signaling, and inflammatory genes, making 12Z cells in monolayer comparable to human endometriotic tissue [39]; 5) 12Z cells molecularly respond to TNF α and IL6 signaling, both of which have been shown to be upregulated in the peritoneal fluid of women with endometriosis [40-42]; and 6) 12Z cells as small spheroids ($\sim 200 \mu\text{m}$) better mimic human endometriosis lesions in histology and gene expression than monolayer [24]. While these previous works were imperative for moving the endometriotic field forward, we aimed to build bigger and more complex constructs assembled from multiple spheroids to better recapitulate endometriosis in women. To do so, we needed to develop building blocks of large spheroids ($\sim 500 \mu\text{m}$) that could be biofabricated.

A spheroid was defined as a tight, dense mass of cells that, if disturbed by agitation or pipetting, the mass did not dissociate. 12Z cells grown in ultra-low attachment round-bottom plates were examined. By 4 hours, cells were distributed evenly along the bottom of the wells (data not shown). At 24 hours, cells had aggregated into a mass, with irregular tufts of cells on the mass's outer edge (Figure 2A). By 48 hours, cells had assembled into a tight, dense mass that maintained its solid structure upon agitation. Examination under bright field microscopy showed the 12Z spheroids at 48 hours were round in shape with smooth regular borders (Figure 2B). Since these spheroids were to be used as building blocks for larger constructs, there was a need to characterize their survival. Spheroids consumed significant amounts of nutrients, as evidenced by pH changes visualized through phenol red-containing media. Visual daily inspection showed no gross changes to spheroids after the initial formation. Proliferation was observed throughout the spheroid as indicated by evenly disbursed Ki-67 expression in sections cut from the center of the spheroid (Figure 2C). Spheroids remained without gross observations of media containing dead cells or spheroids breaking into

smaller pieces. Additionally, cCAS3 was used to assess apoptosis. Spheroids were absent of apoptosis even at the core (Figure 2D). Thus, 12Z cells can be grown and maintained as large spheroids.




Figure 2. Large 12Z spheroids. **A)** At 24 hours, 18,000 12Z cells grown in ultra-low attachment round-bottom 96-well plates appear as a mass of cells with rough irregular edges (black arrowhead). **B)** At 48 hours, 12Z cells have formed a tight spheroid with a dense core (white arrow) and smooth rounded edges (white arrowhead). 12Z spheroids remain alive for at least 120 hours, where spheroids remained **C)** proliferative (Ki-67, red) and **D)** non-apoptotic (cCAS3, red). Blue = DAPI Scale = 400 μ m.

The Regenova Bio 3D Printer uses spheroids as building blocks for more complex biofabricated tissue constructs [29] (Figure 1C). Specific spheroid characteristics need to be met before successful biofabrication. For example, the Kenzan is made up of needles spaced 500 μ m apart. Spheroids that are too small will not fill in the gap between needles, failing to fuse to other spheroids and thus failing to form a larger construct. Alternatively, too large of spheroids may not be placed on the Kenzan properly or may push adjacent spheroids out of place [30]. Thus, 500 μ m spheroids are the optimal size with a tolerability range of 450 – 650 μ m. Based on spheroids successfully biofabricated in the past [30], optimal goal parameters for successful biofabrication were 80-100 roundness (%), 0-5 smoothness (%), and 450-650 diameter (μ m). Using the vision system of the Regenova Bio 3D Printer, spheroid roundness (%), smoothness (%), diameter (μ m) were assessed daily over 120 hours. 12Z cells were seeded at a density of 6000-12,000 cells per well (Figure 3). Consistent with gross visualization via bright field microscopy (Figure 2A), the Regenova Bio 3D Printer did not recognize cells in the plate as spheroids at 24 hours. Spheroids failed recognition by the Regenova Bio 3D Printer if they did not fit all of the user-defined optimal goal parameters [80-100 roundness (%), 0-5 smoothness (%), and 450-650 diameter (μ m)]. In general, 12Z cell masses typically failed at 24 hours because of unmet roundness or smoothness (data not shown). At 48 hours, 12Z cells still failed to meet optimal goal roundness (Figure 3A). By 72 hours, most 12Z cells met optimal roundness and smoothness (grey shading in Figure 3A and 3B). Between 72 and 120 hours, there was little or no change in roundness or smoothness. Time affected the diameter of spheroids (Figure 3C). As

incubation time increased, the diameter converged on a range of 550-650 μm independent of cell density (Figure 3C). Low seeding density, 6,000 cells per well, had consistently fewer round spheroids than all other groups, although, by 96 hours, they met the optimal roundness criteria (Figure 3A). Seeding density did not appear to significantly impact smoothness, except at 48 hours (Figure 3B). At 72 hours, spheroids made from 8,000 12Z cells met all of the optimal goal standards and were used for further biofabrication (Figure 3D).




Figure 3. Large 12Z spheroids used for 3D biofabrication. Optimization for time post-seeding and the number of cells seeded for **A)** roundness, **B)** smoothness, and **C)** diameter. **D)** Representative image of a spheroid which fits all of the Regenova goal parameters. Scale = 400 μm . Grey shading indicates the tolerability range. N = 3.

Previous work suggested that 12Z cells in monolayer were sensitive to serum changes [19]. Therefore, the effects of two different brands of United States-sourced fetal bovine serum on 12Z spheroid roundness, smoothness, and diameter were examined. 12Z cells were grown in either Atlanta Biologicals or Corning fetal bovine serum for two weeks before experiments. No gross differences in cell morphology, media consumption rate, or time to confluence in monolayer were observed (data not shown). Independent of which serum was used, at 72 hours, 12Z cells resulted in tight, dense spheroids (data not shown). No sensitivity to serum brand was seen in either roundness or smoothness (Supplemental Figure S1A). However, spheroids increased in size, dependent on the number of cells seeded when generated in either serum (Supplemental Figure S1A). Fetal bovine serum from Atlanta Biologicals resulted in consistently larger spheroids when compared to spheroids generated in Corning fetal bovine serum at 72 hours (Supplemental Figure S1A). At 72 hours, spheroids generated in Atlanta Biologicals serum ranged from 77-132 μm larger than spheroids generated in Corning serum with the same number of cells seeded. Biofabrication was attempted using spheroids grown in Corning and Atlanta Biologicals fetal bovine serum. For biofabrication, if the spheroid passed the inspection of the user-defined parameters, it was lifted from the 96-well plate via nozzle suction and placed on the Kenzan. Spheroids generated in Corning serum were more

difficult for the suction nozzle to lift from the well. Even with the frequent loosening of the spheroids from the bottom of the well with gentle pipetting and increased suction, the Regenova Bio 3D Printer failed to lift over two-thirds of the spheroids generated in Corning serum. As a result, Atlanta Biologicals serum was used for the remainder of the experiments.

The final condition explored was the passage number of 12Z cells. Since 12Z cells were gifted at an unknown passage number, passage number was defined as early, middle, and late in reference to passaging within our laboratory. Passage number was relative to the number of continual passages since thawing, with early being $< +5$, middle = $+5-15$, and later $> +15$ passages. Roundness and smoothness did not appear to differ based on the passage number of the cells. 12Z cells that were passaged $> +15$ times and then cultured into spheroids tended to become larger, although not statistically significant (Supplemental Figure S1B). Since spheroid generation occurred in all passage numbers of 12Z cells, biofabrication was attempted. During biofabrication attempts, it was noted that $> +15$ passages resulted in spheroids that failed to be lifted by the nozzle. Like the Corning serum, spheroids generated from $> +15$ passaged cells failed to be raised by the suction nozzle even after significant optimization of nozzle gauge and suction pressure. As a result, 12Z cells from $\leq +15$ passages were used for biofabrication. Table 1 gives the details of optimal conditions for 12Z cells for Kenzan biofabrication.

Table 1. Biofabrication conditions for cell lines

	12Z	HEYA8	12Z:T-HESC
Number of Cells/Well	8,000	18,000	2,000:19,000
Time in Culture (Hours)	72	72	72
Nozzle (Gauge)	26	26	26
Nozzle Pressure (kPa)	2	2	2

3.2. Characterization of 12Z Spheroids

In addition to meeting the Regenova Bio 3D Printer biofabrication parameters, these large 12Z cell spheroids needed to maintain properties consistent with the endometriosis. Previous work had shown increased expression of inflammatory response genes in endometriomas [43]. Further, the upregulation of inflammatory factors IL6, IL8, and MCP1 [44-50] has been found in the peritoneal fluid of women with endometriosis. To study if growth in spheroid culture altered these inflammatory factors' secretion, 12Z spheroids were grown. The supernatants from 12Z monolayer and spheroid cultures with the same number of cells and conditions were compared. When grown as spheroids, 12Z cells secreted significantly more IL6, IL8, and MCP1 than monolayer (Figure 4A). Previous work showed that 12Z cells in monolayer respond molecularly to TNF α with increased gene expression of IL6, C-X-C motif chemokine ligand 8 (CXCL8, also referred to as IL8), and chemokine ligand 2 (CCL2, also referred to as MCP1) [40]. Thus, we studied the effects of TNF α stimulation on large 12Z spheroids. Similar to previous studies [40], 12Z cells in monolayer treated with increasing doses of TNF α responded with the increased secretion of IL6, IL8, and MCP1 (Figure 4B). 12Z spheroids treated with TNF α did not show an increase in IL6 or IL8 secretion (Figure 4C). MCP1 secretion did increase in 12Z spheroids when treated with TNF α (Figure 4C). 12Z spheroids were insensitive to TNF α with regard to IL6 and IL8 expression, unlike the high response to TNF α observed in 12Z monolayer.




Figure 4. 12Z cells secrete increased inflammatory factors when grown as large spheroids but lose further sensitivity to TNF α . A) Secreted inflammatory factors are increased in 12Z cells grown as large spheroids compared to monolayer. **B)** Monolayer cells treated with TNF α secrete increased levels of inflammatory cytokines in a dose-response manner. **C)** 12Z spheroids do not similarly respond, with only MCP1 secretion increasing after high doses of TNF α . Note the scale differs between graphs. N \geq 3. * P < 0.05, ** P < 0.01, ***P < 0.001.

Studies have also shown endometriotic cells can metabolize estradiol, potentially exacerbating disease [51,52]. This *de novo* estrogen synthesis may be caused by available cholesterol coupled with increased aromatase [cytochrome p450, family 19a1 (*CYP19A1*)] and hydroxysteroid 17-beta dehydrogenase 1 (*HSD17 β 1*) expression, critical enzymes involved in estradiol synthesis [53-55]. Large 12Z spheroids showed an 8.1-fold increase in *CYP19A1* and a 23-fold increase in *HSD17 β 1* in spheroid than monolayer cultures (Figure 5). Further, 12Z spheroids exhibited a 7.2-fold increase in estrogen receptor type 1 (*ESR1*) compared to monolayer (Figure 5).




Figure 5. Estrogen-related gene expression is dependent on dimensionality in 12Z cells. *CYP19A1* and *HSD17β1*, genes involved in estrogen synthesis, are upregulated in 12Z cells grown as spheroids compared to monolayer. *ESR1*, an estrogen receptor, is also increased in spheroids compared to monolayer. RQ = relative quantification. N ≥ 3. *P < 0.05, **P < 0.01.

3.3. 3D Biofabrication with 12Z Spheroids

3D biofabrication was performed on a 9 × 9 Kenzan. The Kenzan was used as a temporary scaffold allowing the spheroids to be held in position as they fuse to one another (Figure 1). With the robotic assistance of the Regenova Bio 3D Printer, 12Z spheroids (8,000 cells per well, cultured for 72 hours) were biofabricated by stacking three 12Z spheroids in the X and Y dimension and two spheroids in the Z dimension, 3x3x2 (Figure 6A). Constructs were also generated from 2x2x2 and 3x3x3 spheroids (data not shown). After 72 hours, the construct was gently lifted off the Kenzan by one of the two platens (Figure 1B). When constructs were first removed, they retained holes from where the Kenzan needles were (arrow, Figure 6B). These holes were no longer visible within 24 hours, and borders between individual spheroids smoothed. The media was changed every 1-2 days. If constructs were placed in a traditional cell culture dish, they adhered to the dish floor, and cells would proliferate from the construct into monolayer (data not shown). Therefore, constructs were maintained in ultra-low attachment 12-well plates. Constructs were cultured for up to 96 hours with no visual observations of construct degradation or breakage. To test other shapes, 12Z spheroids were biofabricated into a hollow 3x3x3 tube (Figure 6C). Within 24 hours after the construct was removed from the Kenzan, the needle holes had closed and were no longer visible, but the inner channel remained patent (arrowhead, Figure 6C).

0




Figure 6. 3D biofabrication of 12Z and HEYA8 spheroids into constructs. **A)** 12Z spheroids immediately after biofabrication in a 3x3x2 pattern on the Kenzan. White dotted circle = individual spheroid. **B)** Rendering and representative example of the 3x3x2 3D biofabricated cube made from 12Z spheroids < 24 hours after removal from Kenzan. Scale = 200 μ m. Arrow = hole left by Kenzan needle. **C)** Rendering and representative example of a 3D printed tube made from 3x3x3 12Z spheroids > 24 hours after removal from Kenzan. Scale = 200 μ m. Arrowhead = hollow channel. **D)** Rendering and representative construct from a 2x2x2 HEYA8 core surrounded by a 4x4x4 12Z shell. Scale = 200 μ m.

3.4. Multi-Cell Type 3D Biofabrication

A significant portion of non-high-grade serous epithelial ovarian cancers, including endometrioid and clear-cell ovarian adenocarcinomas, are believed to be biologically impacted by the endometriotic microenvironment [12,56]. As a result, modeling endometriosis-associated ovarian cancers using 3D biofabrication techniques may allow for recapitulation of the endometriotic microenvironment. To study ovarian cancer within the endometriotic microenvironment, a malignant ovarian epithelial cell line, HEYA8, which was previously shown to grow as large dense aggregates [26], was selected. HEYA8 cells were optimized for spheroid formation compatible with 3D biofabrication (Supplemental Figure S2). HEYA8 cells did not show sensitivity to serum changes (data not shown). Spheroids generated from 18,000 HEYA8 cells per well were used for biofabrication (Table 1).

Since 12Z cells and HEYA8 are typically maintained in different media (HEYA8, RPMI; 12Z, DMEM/F12), optimization for co-culturing was necessary. 12Z cells were labeled with Td-Tomato and HEYA8 cells with GFP for easy visual recognition under fluorescent microscopy. Fluorescently expressing cells were then grown together in monolayer with seven 12Z cells for every one HEYA8 cell, the final ratio of cell used in constructs described below. The ratio of DMEM/F12 to RPMI media was varied, and the relative cellular density of the two cell types was observed via fluorescent

microscopy at 96 hours (Supplemental Figure S3). The media ratio that best maintained the original seeding ratio (eight DMEM/F12: one RPMI) was used for constructs composed of 12Z and HEYA8 cells. Constructs were biofabricated using spheroids made from 12Z cells and spheroids made from HEYA8 cells. This construct was formed as a 2x2x2 HEYA8 (ovarian cancer) core surrounded by a 4x4x4 12Z (endometriosis epithelium) shell (Figure 6D). This multi cell-type 3D biofabricated construct was greater than 1.5 mm on each side and exhibited smooth edges.

3.5. 3D Biofabrication of Heterotypic Spheroids

Endometriotic lesions have cellular heterogeneity, being comprised of endometrial-like epithelial and stromal cells [1]. Consequently, having stromal cells within the same construct could better represent the endometriotic microenvironment. The T-HESC cell line [33] was chosen as the stromal cells for these experiments because 1) they are a human telomerase-immortalized benign endometrial stromal cell line, allowing for reproducible growth [33], 2) they are commercially available, 3) they have a comparable doubling time to 12Z cells, allowing for alignment of experimental logistic [33], 4) they have cellular, biological, and molecular properties of endometrial stromal cells [33], and 5) they are grown in similar media to 12Z cells, making T-HESC cells a promising stromal cell line to grow with 12Z cells. T-HESC cells were capable of forming tight, dense spheroids that withstood gentle disruption and fit within the Regenova Bio 3D Printer vision parameters for smoothness and diameter, but not roundness (Supplemental Figure S4A-C). Additionally, these spheroids failed to successfully biofabricate on a Kenzan, in two ways. One, some spheroids failed to withstand the suction pressure and were deformed (Supplemental Figure S4D) or were sucked into the waste container, independent of pressure or gauge optimization. Two, spheroids that survived the suction pressure lost integrity upon contact with the Kenzan, leaving only partial spheroid remains, not capable of fusing into constructs (Supplemental Figure S4E).

As a means to overcome the inability to biofabricate T-HESC spheroids alone, T-HESC cells were co-cultured with 12Z cells, creating a heterotypic spheroid. T-HESC cells were marked with GFP, and 12Z cells were labeled with Td-tomato to discern cell types. Total cell number, the ratio of epithelial to stromal cells, and the time in culture were varied to determine optimal spheroid formation conditions (Figure 7A). Heterotypic spheroids made from equal ratios of T-HESC and 12Z cells or a 5:1 ratio failed to survive the pressures of biofabrication. Ratios of 10:1, 15:1, and 20:1 successfully biofabricated (data not shown). For biofabrication of heterotypic spheroids, spheroids were generated from a total of 22,000 cells seeded in a 10:1 (T-HESC:12Z) ratio at 72 hours post-seeding (Table 1). Fluorescent tagging of both cell lines allowed for observation of the intra-spheroidal organization of the two cell types. The fixation protocol was optimized to minimize cellular damage and fluorescent quenching (data not shown). Whole spheroid imaging showed that cells self-organize within the spheroid with 12Z cells creating a shell around a T-HESC core (Figure 7B), as observed in endometrial organoids [57].

Although cellular arrangement within the heterotypic spheroid appeared to self-assemble in a biologically relevant manner, cellular arrangement within the larger construct required testing. Following successful biofabrication of spheroids into a 3x3x3 construct, the constructs were fixed. Immunohistochemistry was used to confirm the self-organization in the constructs. Consistent with the fluorescent markers, KRT7, an epithelial marker, outlined the individual spheroids within the larger construct (Figure 7C), and CD10, a stromal marker, was found inside each individual spheroid (Figure 7D) [58,59]. Accordingly, both spheroids and constructs can be generated, including stromal and epithelial cell types distributed in a biologically relevant manner.




Figure 7. Biofabrication of heterotypic spheroids. **A)** Optimization of diameter for the total number of seeded cells and ratio of T-HESC to 12Z cells at 72 hours post-seeding. The line indicates the tolerability range of Regenova technology. $N = 3$. **B)** Spheroids made from 12Z and T-HESC cells self-assembled with 12Z-epithelial cells (Red) on the outside and T-HESC-stromal cells (Green) on the inside. Scale = 400 μm . **3x3x3** constructs biofabricated from heterotypic spheroids share similar self-assembly with **C)** KRT-7 as an epithelial marker and **D)** CD-10 as a stromal marker. Arrow = epithelial cells (12Z), arrowhead = stromal cells (T-HESC). Scale = 50 μm . Inset Scale = 100 μm .

4. Discussion

Endometriosis research is hindered by the scarcity of representative endometriotic *in vitro* models [16-19]. Our study shows that large spheroids generated from 12Z cells represent human endometriosis characteristics and that complex 3D tissue-like constructs can be successfully biofabricated to model endometriosis and the endometriotic microenvironment. In our experiments, 12Z spheroids were biofabricated into 3D constructs, and complexity was added by including ovarian cancer and stromal cells.

Despite a large number of ovarian cancer cell lines, there are few benign gynecological cell lines modeling diseases such as endometriosis, and even fewer epithelial-like endometriotic cell lines [16-19]. Therefore, we chose to focus on a commercially available immortalized endometriotic epithelial-like cell line, 12Z, as the epithelial cell for these proof-of-concept models. 12Z has become one of the best characterized endometriotic cell lines, leading to molecular and functional insights into endometriosis [21,24,39-42,59-61]. For example, Arosh *et al.* used 12Z cells cultured with and without endometriotic stromal cells to highlight the molecular and preclinical impact of prostaglandin E₂ in endometriosis [60]. Wu *et al.* used 12Z cells with long-term exposure to TNF α to explain the mechanism behind progesterone resistance in endometriotic lesions [42]. Some consider 12Z cells to have properties of benign endometrial cells [62]. We consider 12Z cells in monolayer a reasonable endometriosis model because 12Z cells express estrogen-related [39] and inflammatory genes [40]. Importantly for our work shown here, large 12Z spheroids represented an *in vitro* model of endometriosis in two biologically impactful ways. One, 12Z spheroids secreted increased

inflammatory factors, including IL6, IL8, and MCP1, compared to monolayer, which recapitulates what is seen in women with endometriosis. Inflammatory dysregulation, such as increased TNF α and transforming growth factor-beta signaling, plays a vital role in endometriosis's pathogenesis [17,43,63,64]. Inflammatory cytokines are elevated in endometriosis lesions and peritoneal fluid of women with endometriosis [44-50]. Specifically, elevated IL8 and MCP1 have been shown in the peritoneal fluid of women with endometriosis [65], and IL6, in the peritoneal fluid, has been linked to infertility in women with endometriosis [66]. Thus, the recapitulation of inflammatory dysregulation is a necessary characteristic of a robust *in vitro* model. Grund *et al.* previously showed that 12Z cells stimulated with TNF α increased inflammatory signaling [40]. We showed that 12Z cells in monolayer express undetectable or low levels of inflammatory cytokines, but similar to Grund *et al.* [40], TNF α stimulation increased secretion of IL6, IL8, and MCP1. This data suggests that monolayer 12Z cells require outside stimuli to represent the inflammatory microenvironment seen in women with endometriosis.

In contrast, we showed that 12Z cells could reproduce the robust inflammatory signaling without the need for additional stimulation if they are grown as large 3D spheroids. Our work using secreted cytokines supports gene expression data from small 12Z spheroids previously reported [24]. We further challenged this robust inflammatory phenotype by treating spheroids with TNF α , where neither IL6 nor IL8 responded. Interestingly, MCP1 did increase in response to TNF α treatment. This dichotomous response may indicate that IL6 and IL8 are induced through separate mechanisms from MCP1 in endometriosis. It has been suggested that through non-genomic pathways, increased estrogen signaling in endometriosis can stimulate MCP1 [67]. Therefore, one hypothesis suggests that increased estrogen signaling in 12Z spheroids may be driving the MCP1 secretion, allowing for TNF α stimulation to exacerbate the secretion. Additional hypotheses could offer other TNF α -independent pathways or that IL6 and IL8 reached a ceiling, and thus, no further response after TNF α stimulation was possible. Further testing is needed to explore this effect. Nevertheless, 12Z spheroids can be used to model endometriosis-related inflammation with less need for cellular manipulation and may provide fascinating insights into the pathogenesis of endometriosis-related inflammation.

Two, the 12Z *in vitro* spheroid model represented endometriosis with elevated levels of estrogen-related genes: *CYP19A1*, *HSD17 β 1*, and *ESR1*. These data suggest that 3D biofabricated constructs may be a good representation of human disease. Current medical therapies for endometriosis target the reduction of estradiol levels since endometriosis is an estrogen-responsive disease [2]. Both endometriotic lesions and 12Z cells have been shown to express *ESR1*, allowing estrogen response [21,68]. Here, we showed that *ESR1* gene expression was significantly increased when 12Z cells were grown as spheroids. This result suggests that 12Z spheroids are more estrogen-responsive, although additional testing will need to be completed. Studies indicate that endometriotic lesions themselves may produce exogenous estrogen through available cholesterol and increased aromatase [68]. We showed that 12Z spheroids have an increase in *CYP19A1*, which was previously reported in small 12Z spheroids [24]. *HSD17 β 1* encodes for the enzyme responsible for estrone conversion to the bio-actively available 17 β -estradiol. *HSD17 β 1* is expressed in 12Z monolayer cells [39] but is expressed at increased levels in 3D spheroids. In total, we showed that culturing 12Z cells into large spheroids significantly stimulates expression of genes involved in estrogen synthesis, suggesting that 12Z 3D spheroids can be used to study the exogenous expression of estrogen in endometriosis.

While spheroid models do pose a better way to *in vitro* model human disease, limitations like the inability to recapitulate a tumor's complexity due to small size and lack of microenvironment interactions still remain [69]. Therefore, we used the Kenzan method of biofabrication to increase both size and complexity of endometriotic *in vitro* models. The Kenzan method allows for larger constructs by using spheroids as building blocks. Here, we increased the size of the *in vitro* model to 27X the original spheroid size. In addition to allowing for increased size, the Kenzan method supports highly reproducible and versatile constructs, allowing for better recapitulation of tissue interaction and biologically relevant shapes [31]. The Regenova Bio 3D Printer's robotic arm allows for precise placement in the X, Y, and Z dimensions on the Kenzan, increasing reproducibility. We showed 12Z spheroids could be biofabricated into multiple shapes and sizes, including cubes and hollow tubes. Our dense cube constructs can be used to model tumors, while the tube structures can be used to

study perfusion and disseminate cells. These results represent proof-of-concept data that the Kenzan method can produce scaffold-free constructs made from an endometriotic cell line. These constructs may better recapitulate endometriotic cell responses to environmental or treatment stimulation.

Biofabricated constructs not only allow for larger size and more shapes but can be used to model the microenvironment and cellular interactions. Here, novel *in vitro* modeling of the endometriotic microenvironment has been demonstrated by generating complex 3D biofabricated tissue-like constructs. Lee *et al.* previously described the ability for many different epithelial ovarian cell lines to form or fail to form spheroids [26]. This body of work was substantial and beneficial for the early development of 3D cell cultures to model ovarian disease. It was used here to choose a malignant cell line to biofabricate into constructs. The HEYA8 cell line formed tight, dense spheroids [26] and has been well characterized molecularly as non-high-grade serous [70,71]. To create an *in vitro* model of the endometriotic microenvironment, we biofabricated multi-cell type 3D constructs with HEYA8 and 12Z spheroids. Specifically, multi-cell type 3D constructs were biofabricated from a core of malignant HEYA8 cells surrounded by a shell of benign 12Z cells. To our knowledge, this is the first Kenzan construct formed from two distinct monotypic spheroids. This multi-cell type construct is a proof-of-concept that the endometriotic microenvironment can be modeled through the Kenzan method. Further investigation of the intercellular interactions may provide insights into how benign and malignant tissue impact one another. Confirmation of cellular organization, invasion, migration, and fusion across cell types should be examined to investigate the natural dispersion after culturing together.

Complex 3D *in vitro* models have previously been developed and are used for gynecological studies in endometrial and ovarian regeneration [72-76] and cervical remodeling [77-79]. For instance, to recapitulate the hypothalamic-pituitary-ovarian axis, researchers have built a microfluidic system using a chemical scaffold material [74]. Unfortunately, scaffold materials can impose severe limitations on cellular diversity, viability, and intercellular communication [69,80]. Specifically, naturally- or synthetically-derived scaffold materials tend to prevent normal interactions causing poor replication of normal tissue. Natural tissue development utilizes input from both cell-cell and cell-extracellular matrix interactions to determine proper nutrient and waste transfer [69,80,81]. These biologic requirements pose a challenge for engineering endometriosis and endometriotic microenvironment tissue models. The Kenzan method [29] allows for the production of scaffold-free tissue-like constructs. For biofabrication, the Kenzan is used as a temporary scaffold, relying on cells to deposit native, biologically-optimized extracellular matrix. The constructs are then removed from the Kenzan, leaving a fully scaffold-free construct. Here, we showed the robust potential of the Kenzan method to produce scaffold-free tissue-like constructs.

Finally, endometriosis and the endometriotic microenvironment are challenging to investigate due to the high complexity of the intercellular communication between unique cell types, including endometrial epithelium and stroma. To better represent endometriotic tissue *in vitro*, the complexity of 3D biofabricated tissue-like constructs was increased using heterotypic spheroids generated from T-HESC and 12Z cells. 3D modeling of endometriosis has previously been established using long-term expandable organoid models from primary tissue that recapitulated disease traits and common mutations [75,82]. But primary cell models pose a risk of limited reproducibly due to limited tissue availability. Both the 12Z and T-HESC cells are immortalized and commercially available, resulting in increased reproducibility and availability. Also, 12Z [21] and T-HESC [33] cells have a relatively quick doubling time allowing for sufficient cell density to generate spheroids, and spheroids can be generated in 72 hours. Additionally, while organoid models recapitulate some disease traits, they are constrained to a relatively small size [75,82] or can take weeks to months to form large organoids [83]. Here, we show that spheroids can be used as building blocks to generate larger constructs, and 72 hours was sufficient time on the Kenzan for spheroids to fuse into larger tissue constructs. Therefore, time from monolayer to fully formed large scaffold-free tissue constructs (Figure 6) is less than one week.

Endometriosis is pathologically composed of both epithelial and stromal cells. To bring this biologic relevance to our model, T-HESC cells were added to 12Z cells in heterotypic spheroids. T-HESC cells are considered a normal endometrial stromal cell line and not endometriotic, allowing for

the unique ability to study the epithelium's role in endometriosis pathogenesis. Endometriotic stromal cells can and should be supplemented for T-HESC in the future to explore the part of the endometriotic stromal cells in the pathogenesis of endometriosis. T-HESC cells were successfully generated as monotypic spheroids but failed to meet the Regenova Bio 3D Printer standards and the pressures of the suction nozzle during biofabrication. T-HESC cells may produce less extracellular matrix naturally, thus providing less stability to the overall structure. Our goal is to have biologically relevant cellular interactions. We optimized heterotypic spheroids, spheroids composed of both epithelial cells and stromal cells. Excitingly, our findings indicate the heterotypic spheroids self-assembled in a biologically meaningful way [57]. At seeding, the cells were a homogenous mixture of T-HESC and 12Z cells. After spheroid formation, T-HESC cells had condensed in the center while being surrounded by a 12Z shell. When spheroids were biofabricated into larger constructs, they maintained their core and shell pattern. However, long-term culturing may result in epithelial cells from individual spheroids migrating out to the construct boundaries. While this is not the first construct biofabricated using the Kenzan method from heterotypic spheroids [84], to our knowledge, it is the first using immortalized cells and modeling gynecological disorders.

5. Conclusions

In conclusion, we have shown that 12Z cells can be grown as large spheroids, capable of surviving Kenzan method 3D biofabrication. These large spheroids represent the inflammatory and estrogen-related gene expression of endometriosis. These large 12Z spheroids can be used as building blocks to generate representative tissue-like 3D biofabricated models of endometriosis and the endometriotic microenvironment. We have provided proof-of-concept constructs which may lead to more complex, larger constructs of endometriotic *in vitro* models. Specifically, we have demonstrated the ability to culture constructs in biologically relevant shapes, dense cubes modeling tumors and tubes modeling perfused tissues, and demonstrated constructs with multiple cell types to study cellular interactions.

Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1: 12Z cell spheroids were sensitive to changes in serum. Figure S2: Optimization of time and number of seeded cells for the spheroid formation and successful biofabrication of HEYA8 cells. Figure S3: co-culturing cells in monolayer to determine optimal media. Figure S4: T-HESC cells formed spheroids but failed to meet all of the Regenova Bio 3D Printer criteria for biofabrication.

Author Contributions: Conceptualization, Jillian R. H. Wendel, Xiyin Wang, Lester J. Smith and Shannon M. Hawkins; Data curation, Jillian R. H. Wendel, Xiyin Wang, Lester J. Smith and Shannon M. Hawkins; Formal analysis, Jillian R. H. Wendel, Xiyin Wang, Lester J. Smith and Shannon M. Hawkins; Methodology, Jillian R. H. Wendel, Xiyin Wang, Lester J. Smith and Shannon M. Hawkins; Writing – original draft, Jillian R. H. Wendel and Shannon M. Hawkins; Writing – review & editing, Jillian R. H. Wendel, Xiyin Wang, Lester J. Smith and Shannon M. Hawkins.

Funding: This research was funded by Indiana University Simon Cancer Center Associate Pilot Funding Mechanism, by a grant from the Rivkin Center for Ovarian Cancer, and a Bridge award from the American Associations of Obstetricians and Gynecologists Foundation (AAOGF). Research reported in this publication was also supported by the Office of The Director, National Institutes of Health of the National Institutes of Health under Award Number S10OD023595, and the Indiana Clinical and Translational Sciences Institute, funded in part by grant UL1TR001108 from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award and the Advanced in Medicine grant from Cook Medical. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or Cook Medical.

Acknowledgments: Authors would like to thank Kaitlyn Collins and Dr. Yuliya Klymenko for their valuable input in the editing process of this manuscript and Matthew Dunn for his artistic rendering of the Kenzan method. The authors would like to acknowledge and thank Dr. Asgi Fazleabas for providing the 12Z cell line. The Cell-Based Assay Screening Service Core supported this project at Baylor College of Medicine with funding

from the NIH (P30 CA125123) and Drs. Dan Liu and Jun Xu expert assistance. Data were acquired at the 3D Bioprinting Core facility using the Cyfuse Regenova Bio 3D Printer. This work was supported by the Histology Core of the Indiana Center for Musculoskeletal Health at IU School of Medicine and the Bone and Body Composition Core of the Indiana Clinical Translational Sciences Institute (CTSI). We thank the Multiplex Analysis Core at the Indiana University Melvin and Bren Simon Cancer Center for providing support in analyzing samples and interpretation of data.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Zondervan, K.T.; Becker, C.M.; Koga, K.; Missmer, S.A.; Taylor, R.N.; Vigano, P. Endometriosis. *Nat Rev Dis Primers* **2018**, *4*, 9, doi:10.1038/s41572-018-0008-5.
2. Zondervan, K.T.; Becker, C.M.; Missmer, S.A. Endometriosis. *N Engl J Med* **2020**, *382*, 1244-1256, doi:10.1056/NEJMra1810764.
3. Bulun, S.E.; Yilmaz, B.D.; Sison, C.; Miyazaki, K.; Bernardi, L.; Liu, S.; Kohlmeier, A.; Yin, P.; Milad, M.; Wei, J. Endometriosis. *Endocr Rev* **2019**, *40*, 1048-1079, doi:10.1210/er.2018-00242.
4. Culley, L.; Law, C.; Hudson, N.; Denny, E.; Mitchell, H.; Baumgarten, M.; Raine-Fenning, N. The social and psychological impact of endometriosis on women's lives: a critical narrative review. *Hum Reprod Update* **2013**, *19*, 625-639, doi:10.1093/humupd/dmt027.
5. Taylor, R.N.; Hummelshoj, L.; Stratton, P.; Vercellini, P. Pain and endometriosis: Etiology, impact, and therapeutics. *Middle East Fertil Soc J* **2012**, *17*, 221-225, doi:10.1016/j.mefs.2012.09.002.
6. Nnoaham, K.E.; Hummelshoj, L.; Webster, P.; d'Hooghe, T.; de Cicco Nardone, F.; de Cicco Nardone, C.; Jenkinson, C.; Kennedy, S.H.; Zondervan, K.T.; World Endometriosis Research Foundation Global Study of Women's Health, c. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. *Fertil Steril* **2011**, *96*, 366-373 e368, doi:10.1016/j.fertnstert.2011.05.090.
7. Fourquet, J.; Baez, L.; Figueroa, M.; Iriarte, R.I.; Flores, I. Quantification of the impact of endometriosis symptoms on health-related quality of life and work productivity. *Fertil Steril* **2011**, *96*, 107-112, doi:10.1016/j.fertnstert.2011.04.095.
8. Fourquet, J.; Gao, X.; Zavala, D.; Orengo, J.C.; Abac, S.; Ruiz, A.; Laboy, J.; Flores, I. Patients' report on how endometriosis affects health, work, and daily life. *Fertil Steril* **2010**, *93*, 2424-2428, doi:10.1016/j.fertnstert.2009.09.017.
9. De Graaff, A.A.; D'Hooghe, T.M.; Dunselman, G.A.; Dirksen, C.D.; Hummelshoj, L.; Consortium, W.E.; Simoens, S. The significant effect of endometriosis on physical, mental and social wellbeing: results from an international cross-sectional survey. *Hum Reprod* **2013**, *28*, 2677-2685, doi:10.1093/humrep/det284.
10. Simoens, S.; Dunselman, G.; Dirksen, C.; Hummelshoj, L.; Bokor, A.; Brandes, I.; Brodzszy, V.; Canis, M.; Colombo, G.L.; DeLeire, T., et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. *Hum Reprod* **2012**, *27*, 1292-1299, doi:10.1093/humrep/des073.
11. Simoens, S.; Hummelshoj, L.; D'Hooghe, T. Endometriosis: cost estimates and methodological perspective. *Hum Reprod Update* **2007**, *13*, 395-404, doi:10.1093/humupd/dmm010.
12. Worley, M.J.; Welch, W.R.; Berkowitz, R.S.; Ng, S.W. Endometriosis-associated ovarian cancer: a review of pathogenesis. *Int J Mol Sci* **2013**, *14*, 5367-5379, doi:10.3390/ijms14035367.
13. Wang, C.; Liang, Z.; Liu, X.; Zhang, Q.; Li, S. The Association between Endometriosis, Tubal Ligation, Hysterectomy and Epithelial Ovarian Cancer: Meta-Analyses. *Int J Environ Res Public Health* **2016**, *13*, 1138, doi:10.3390/ijerph13111138.
14. Pearce, C.L.; Templeman, C.; Rossing, M.A.; Lee, A.; Near, A.M.; Webb, P.M.; Nagle, C.M.; Doherty, J.A.; Cushing-Haugen, K.L.; Wicklund, K.G., et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. *Lancet Oncol* **2012**, *13*, 385-394, doi:10.1016/S1470-2045(11)70404-1.

15. Hermens, M.; van Altena, A.M.; Nieboer, T.E.; Schoot, B.C.; van Vliet, H.; Siebers, A.G.; Bekkers, R.L.M. Incidence of endometrioid and clear-cell ovarian cancer in histological proven endometriosis: the ENOCA population-based cohort study. *Am J Obstet Gynecol* **2020**, *223*, 107 e101-107 e111, doi:10.1016/j.ajog.2020.01.041.
16. Fan, H. In-vitro models of human endometriosis. *Exp Ther Med* **2020**, *19*, 1617-1625, doi:10.3892/etm.2019.8363.
17. Wendel, J.R.H.; Wang, X.; Hawkins, S.M. The Endometriotic Tumor Microenvironment in Ovarian Cancer. *Cancers (Basel)* **2018**, *10*, E261, doi:10.3390/cancers10080261.
18. Samimi, G.; Sathyamoorthy, N.; Ting, C.M.; Mazloomdoost, D.; Conroy, J.; Heckman-Stoddard, B.; Halvorson, L.M. Report of the National Cancer Institute and the Eunice Kennedy Shriver National Institute of Child Health and Human Development-sponsored workshop: gynecology and women's health-benign conditions and cancer. *Am J Obstet Gynecol* **2020**, 10.1016/j.ajog.2020.08.049, doi:10.1016/j.ajog.2020.08.049.
19. Romano, A.; Xanthoulea, S.; Giacomini, E.; Delvoux, B.; Alleva, E.; Vigano, P. Endometriotic cell culture contamination and authenticity: a source of bias in in vitro research? *Hum Reprod* **2020**, *35*, 364-376, doi:10.1093/humrep/dez266.
20. Holdsworth-Carson, S.J.; Colgrave, E.M.; Donoghue, J.F.; Fung, J.N.; Churchill, M.L.; Mortlock, S.; Paiva, P.; Healey, M.; Montgomery, G.W.; Girling, J.E., et al. Generation of immortalized human endometrial stromal cell lines with different endometriosis risk genotypes. *Mol Hum Reprod* **2019**, *25*, 194-205, doi:10.1093/molehr/gaz006.
21. Zeitvogel, A.; Baumann, R.; Starzinski-Powitz, A. Identification of an invasive, N-cadherin-expressing epithelial cell type in endometriosis using a new cell culture model. *The American journal of pathology* **2001**, *159*, 1839-1852, doi:10.1016/S0002-9440(10)63030-1.
22. Bono, Y.; Kyo, S.; Takakura, M.; Maida, Y.; Mizumoto, Y.; Nakamura, M.; Nomura, K.; Kiyono, T.; Inoue, M. Creation of immortalised epithelial cells from ovarian endometrioma. *Br J Cancer* **2012**, *106*, 1205-1213, doi:10.1038/bjc.2012.26.
23. Kunz-Schughart, L.A.; Freyer, J.P.; Hofstaedter, F.; Ebner, R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. *J Biomol Screen* **2004**, *9*, 273-285, doi:10.1177/1087057104265040.
24. Brueggmann, D.; Templeman, C.; Starzinski-Powitz, A.; Rao, N.P.; Gayther, S.A.; Lawrenson, K. Novel three-dimensional in vitro models of ovarian endometriosis. *J Ovarian Res* **2014**, *7*, 17, doi:10.1186/1757-2215-7-17.
25. Kouroupis, D.; Bowles, A.; Willman, M.A.; Kaplan, L.; Correa, D. Enhanced immunomodulatory profile of infrapatellar fat pad (IFP)-derived MSC after inflammatory priming, 3D spheroid culture and CD146 selection: a cellular alternative for bone marrow (BM) in orthopedics. *Cytotherapy* **2019**, *21*, S66-S67, doi:10.1016/j.jcyt.2019.03.454.
26. Lee, J.M.; Mhawech-Fauceglia, P.; Lee, N.; Parsanian, L.C.; Lin, Y.G.; Gayther, S.A.; Lawrenson, K. A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro. *Lab Invest* **2013**, *93*, 528-542, doi:10.1038/labinvest.2013.41.
27. Yamanaka, K.; Xu, B.; Saganuma, I.; Kusuki, I.; Mita, S.; Shimizu, Y.; Mizuguchi, K.; Kitawaki, J. Dienogest inhibits aromatase and cyclooxygenase-2 expression and prostaglandin E(2) production in human endometriotic stromal cells in spheroid culture. *Fertil Steril* **2012**, *97*, 477-482, doi:10.1016/j.fertnstert.2011.11.005.

28. Ichioka, M.; Mita, S.; Shimizu, Y.; Imada, K.; Kiyono, T.; Bono, Y.; Kyo, S. Dienogest, a synthetic progestin, down-regulates expression of CYP19A1 and inflammatory and neuroangiogenesis factors through progesterone receptor isoforms A and B in endometriotic cells. *J Steroid Biochem Mol Biol* **2015**, *147*, 103-110, doi:10.1016/j.jsbmb.2014.12.008.

29. Moldovan, N.I.; Hibino, N.; Nakayama, K. Principles of the Kenzan Method for Robotic Cell Spheroid-Based Three-Dimensional Bioprinting^{sup}. *Tissue Eng Part B Rev* **2017**, *23*, 237-244, doi:10.1089/ten.TEB.2016.0322.

30. Aguilar, I.N.; Olivos, D.J., 3rd; Brinker, A.; Alvarez, M.B.; Smith, L.J.; Chu, T.G.; Kacena, M.A.; Wagner, D.R. Scaffold-free bioprinting of mesenchymal stem cells using the Regenova printer: Spheroid characterization and osteogenic differentiation. *Bioprinting* **2019**, *15*, doi:10.1016/j.bprint.2019.e00050.

31. Aguilar, I.N.; Smith, L.J.; Olivos, D.J., 3rd; Chu, T.G.; Kacena, M.A.; Wagner, D.R. Scaffold-free Bioprinting of Mesenchymal Stem Cells with the Regenova Printer: Optimization of Printing Parameters. *Bioprinting* **2019**, *15*, doi:10.1016/j.bprint.2019.e00048.

32. Mills, G.B.; May, C.; Hill, M.; Campbell, S.; Shaw, P.; Marks, A. Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. *J Clin Invest* **1990**, *86*, 851-855, doi:10.1172/JCI114784.

33. Krikun, G.; Mor, G.; Alvero, A.; Guller, S.; Schatz, F.; Sapi, E.; Rahman, M.; Caze, R.; Qumsiyeh, M.; Lockwood, C.J. A novel immortalized human endometrial stromal cell line with normal progestational response. *Endocrinology* **2004**, *145*, 2291-2296, doi:10.1210/en.2003-1606.

34. Graham, F.L.; Smiley, J.; Russell, W.C.; Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. *J Gen Virol* **1977**, *36*, 59-74, doi:10.1099/0022-1317-36-1-59.

35. Yu, Z.; Kim, J.; He, L.; Creighton, C.J.; Gunaratne, P.H.; Hawkins, S.M.; Matzuk, M.M. Functional analysis of miR-34c as a putative tumor suppressor in high-grade serous ovarian cancer. *Biol Reprod* **2014**, *91*, 113, doi:10.1095/biolreprod.114.121988.

36. Aghajanova, L.; Hamilton, A.; Kwintkiewicz, J.; Vo, K.C.; Giudice, L.C. Steroidogenic enzyme and key decidualization marker dysregulation in endometrial stromal cells from women with versus without endometriosis. *Biol Reprod* **2009**, *80*, 105-114, doi:10.1095/biolreprod.108.070300.

37. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Met* **2001**, *25*, 402-408, doi:10.1006/meth.2001.1262.

38. Sidak, Z. Rectangular confidence regions for the means of multivariate normal distributions. *Journal of the American Statistical Association* **1967**, *62*, 626-633.

39. Banu, S.K.; Lee, J.; Starzinski-Powitz, A.; Arosh, J.A. Gene expression profiles and functional characterization of human immortalized endometriotic epithelial and stromal cells. *Fertil Steril* **2008**, *90*, 972-987, doi:10.1016/j.fertnstert.2007.07.1358.

40. Grund, E.M.; Kagan, D.; Tran, C.A.; Zeitvogel, A.; Starzinski-Powitz, A.; Nataraja, S.; Palmer, S.S. Tumor necrosis factor-alpha regulates inflammatory and mesenchymal responses via mitogen-activated protein kinase kinase, p38, and nuclear factor kappaB in human endometriotic epithelial cells. *Mol Pharmacol* **2008**, *73*, 1394-1404, doi:10.1124/mol.107.042176.

41. Schneider, C.; Kassens, N.; Greve, B.; Hassan, H.; Schuring, A.N.; Starzinski-Powitz, A.; Kiesel, L.; Seidler, D.G.; Gotte, M. Targeting of syndecan-1 by micro-ribonucleic acid miR-10b modulates invasiveness of endometriotic cells via dysregulation of the proteolytic milieu and interleukin-6 secretion. *Fertil Steril* **2013**, *99*, 871-881 e871, doi:10.1016/j.fertnstert.2012.10.051.

42. Wu, Y.; Starzinski-Powitz, A.; Guo, S.W. Prolonged stimulation with tumor necrosis factor-alpha induced partial methylation at PR-B promoter in immortalized epithelial-like endometriotic cells. *Fertil Steril* **2008**, *90*, 234-237, doi:10.1016/j.fertnstert.2007.06.008.

43. Hawkins, S.M.; Creighton, C.J.; Han, D.Y.; Zariff, A.; Anderson, M.L.; Gunaratne, P.H.; Matzuk, M.M. Functional microRNA involved in endometriosis. *Mol Endocrinol* **2011**, *25*, 821-832, doi:10.1210/me.2010-0371.

44. Harada, T.; Yoshioka, H.; Yoshida, S.; Iwabe, T.; Onohara, Y.; Tanikawa, M.; Terakawa, N. Increased interleukin-6 levels in peritoneal fluid of infertile patients with active endometriosis. *Am J Obstet Gynecol* **1997**, *176*, 593-597, doi:10.1016/s0002-9378(97)70553-2.

45. Rana, N.; Braun, D.P.; House, R.; Gebel, H.; Rotman, C.; Dmowski, W.P. Basal and stimulated secretion of cytokines by peritoneal macrophages in women with endometriosis. *Fertil Steril* **1996**, *65*, 925-930.

46. Akoum, A.; Lemay, A.; McColl, S.; Turcot-Lemay, L.; Maheux, R. Elevated concentration and biologic activity of monocyte chemotactic protein-1 in the peritoneal fluid of patients with endometriosis. *Fertil Steril* **1996**, *66*, 17-23.

47. Eisermann, J.; Gast, M.J.; Pineda, J.; Odem, R.R.; Collins, J.L. Tumor necrosis factor in peritoneal fluid of women undergoing laparoscopic surgery. *Fertil Steril* **1988**, *50*, 573-579, doi:10.1016/s0015-0282(16)60185-1.

48. Calhaz-Jorge, C.; Costa, A.P.; Barata, M.; Santos, M.C.; Melo, A.; Palma-Carlos, M.L. Tumour necrosis factor alpha concentrations in the peritoneal fluid of infertile women with minimal or mild endometriosis are lower in patients with red lesions only than in patients without red lesions. *Hum Reprod* **2000**, *15*, 1256-1260, doi:10.1093/humrep/15.6.1256.

49. Jin, C.H.; Yi, K.W.; Ha, Y.R.; Shir, J.H.; Park, H.T.; Kim, T.; Hur, J.Y. Chemerin Expression in the Peritoneal Fluid, Serum, and Ovarian Endometrioma of Women with Endometriosis. *Am J Reprod Immunol* **2015**, *74*, 379-386, doi:10.1111/aji.12405.

50. Young, V.J.; Brown, J.K.; Saunders, P.T.; Duncan, W.C.; Horne, A.W. The peritoneum is both a source and target of TGF-beta in women with endometriosis. *PLoS One* **2014**, *9*, e106773, doi:10.1371/journal.pone.0106773.

51. Giudice, L.C.; Kao, L.C. Endometriosis. *Lancet* **2004**, *364*, 1789-1799, doi:10.1016/S0140-6736(04)17403-5.

52. Bulun, S.E.; Yang, S.; Fang, Z.; Gurates, B.; Tamura, M.; Zhou, J.; Sebastian, S. Role of aromatase in endometrial disease. *J Steroid Biochem Mol Biol* **2001**, *79*, 19-25, doi:10.1016/s0960-0760(01)00134-0.

53. Noble, L.S.; Simpson, E.R.; Johns, A.; Bulun, S.E. Aromatase expression in endometriosis. *J Clin Endocrinol Metab* **1996**, *81*, 174-179, doi:10.1210/jcem.81.1.8550748.

54. Zeitoun, K.; Takayama, K.; Michael, M.D.; Bulun, S.E. Stimulation of aromatase P450 promoter (II) activity in endometriosis and its inhibition in endometrium are regulated by competitive binding of steroidogenic factor-1 and chicken ovalbumin upstream promoter transcription factor to the same cis-acting element. *Mol Endocrinol* **1999**, *13*, 239-253, doi:10.1210/mend.13.2.0229.

55. Chantalat, E.; Valera, M.C.; Vaysse, C.; Noirrit, E.; Rusidze, M.; Weyl, A.; Vergriete, K.; Buscail, E.; Lluel, P.; Fontaine, C., et al. Estrogen Receptors and Endometriosis. *Int J Mol Sci* **2020**, *21*, doi:10.3390/ijms21082815.

56. Zhang, C.; Wang, X.; Anaya, Y.; Parodi, L.; Cheng, L.; Anderson, M.L.; Hawkins, S.M. Distinct molecular pathways in ovarian endometrioid adenocarcinoma with concurrent endometriosis. *Int J Cancer* **2018**, *143*, 2505-2515, doi:10.1002/ijc.31768.

57. Murphy, A.R.; Wiwatpanit, T.; Lu, Z.; Davaadelger, B.; Kim, J.J. Generation of Multicellular Human Primary Endometrial Organoids. *J Vis Exp* **2019**, 10.3791/60384, doi:10.3791/60384.

58. McCluggage, W.G.; Sumathi, V.P.; Maxwell, P. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. *Histopathology* **2001**, *39*, 273-278, doi:10.1046/j.1365-2559.2001.01215.x.

59. Dietze, R.; Starzinski-Powitz, A.; Scheiner-Bobis, G.; Tinneberg, H.R.; Meinhold-Heerlein, I.; Konrad, L. Lysophosphatidic acid triggers cathepsin B-mediated invasiveness of human endometriotic cells. *Biochim Biophys Acta Mol Cell Biol Lipids* **2018**, *1863*, 1369-1377, doi:10.1016/j.bbapli.2018.08.013.

60. Arosh, J.A.; Lee, J.; Balasubramanian, D.; Stanley, J.A.; Long, C.R.; Meagher, M.W.; Osteen, K.G.; Bruner-Tran, K.L.; Burghardt, R.C.; Starzinski-Powitz, A., et al. Molecular and preclinical basis to inhibit PGE2 receptors EP2 and EP4 as a novel nonsteroidal therapy for endometriosis. *Proc Natl Acad Sci U S A* **2015**, *112*, 9716-9721, doi:10.1073/pnas.1507931112.

61. Klemmt, P.A.B.; Starzinski-Powitz, A. Molecular and Cellular Pathogenesis of Endometriosis. *Curr Womens Health Rev* **2018**, *14*, 106-116, doi:10.2174/1573404813666170306163448.

62. Wilson, M.R.; Reske, J.J.; Holladay, J.; Wilber, G.E.; Rhodes, M.; Koeman, J.; Adams, M.; Johnson, B.; Su, R.W.; Joshi, N.R., et al. ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion. *Nat Commun* **2019**, *10*, 3554, doi:10.1038/s41467-019-11403-6.

63. Lessey, B.A.; Kim, J.J. Endometrial receptivity in the eutopic endometrium of women with endometriosis: it is affected, and let me show you why. *Fertil Steril* **2017**, *108*, 19-27, doi:10.1016/j.fertnstert.2017.05.031.

64. Capobianco, A.; Rovere-Querini, P. Endometriosis, a disease of the macrophage. *Front Immunol* **2013**, *4*, 9, doi:10.3389/fimmu.2013.00009.

65. Jorgensen, H.; Hill, A.S.; Beste, M.T.; Kumar, M.P.; Chiswick, E.; Fedorcsak, P.; Isaacson, K.B.; Lauffenburger, D.A.; Griffith, L.G.; Qvigstad, E. Peritoneal fluid cytokines related to endometriosis in patients evaluated for infertility. *Fertil Steril* **2017**, *107*, 1191-1199 e1192, doi:10.1016/j.fertnstert.2017.03.013.

66. Wang, X.M.; Ma, Z.Y.; Song, N. Inflammatory cytokines IL-6, IL-10, IL-13, TNF-alpha and peritoneal fluid flora were associated with infertility in patients with endometriosis. *Eur Rev Med Pharmacol Sci* **2018**, *22*, 2513-2518, doi:10.26355/eurrev_201805_14899.

67. Boucher, A.; Mourad, W.; Mailloux, J.; Lemay, A.; Akoum, A. Ovarian hormones modulate monocyte chemotactic protein-1 expression in endometrial cells of women with endometriosis. *Mol Hum Reprod* **2000**, *6*, 618-626, doi:10.1093/molehr/6.7.618.

68. Bulun, S.E.; Cheng, Y.H.; Pavone, M.E.; Xue, Q.; Attar, E.; Trukhacheva, E.; Tokunaga, H.; Utsunomiya, H.; Yin, P.; Luo, X., et al. Estrogen receptor-beta, estrogen receptor-alpha, and progesterone resistance in endometriosis. *Semin Reprod Med* **2010**, *28*, 36-43, doi:10.1055/s-0029-1242991.

69. Katt, M.E.; Placone, A.L.; Wong, A.D.; Xu, Z.S.; Se arson, P.C. In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform. *Front Bioeng Biotechnol* **2016**, *4*, 12, doi:10.3389/fbioe.2016.00012.

70. Beaufort, C.M.; Helmijr, J.C.; Piskorz, A.M.; Hoogstraat, M.; Ruigrok-Ritstier, K.; Besselink, N.; Murtaza, M.; van, I.W.F.; Heine, A.A.; Smid, M., et al. Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. *PLoS One* **2014**, *9*, e103988, doi:10.1371/journal.pone.0103988.

71. Domcke, S.; Sinha, R.; Levine, D.A.; Sander, C.; Schultz, N. Evaluating cell lines as tumour models by comparison of genomic profiles. *Nat Commun* **2013**, *4*, 2126, doi:10.1038/ncomms3126.

72. Hiraoka, T.; Hirota, Y.; Saito-Fujita, T.; Matsuo, M.; Egashira, M.; Matsumoto, L.; Haraguchi, H.; Dey, S.K.; Furukawa, K.S.; Fujii, T., et al. STAT3 accelerates uterine epithelial regeneration in a mouse model of decellularized uterine matrix transplantation. *JCI Insight* **2016**, *1*, doi:10.1172/jci.insight.87591.

73. Olalekan, S.A.; Burdette, J.E.; Getsios, S.; Woodruff, T.K.; Kim, J.J. Development of a novel human recellularized endometrium that responds to a 28-day hormone treatment. *Biol Reprod* **2017**, *96*, 971-981, doi:10.1093/biolre/iox039.

74. Xiao, S.; Coppeta, J.R.; Rogers, H.B.; Isenberg, B.C.; Zhu, J.; Olalekan, S.A.; McKinnon, K.E.; Dokic, D.; Rashedi, A.S.; Haisenleder, D.J., et al. A microfluidic culture model of the human reproductive tract and 28-day menstrual cycle. *Nat Commun* **2017**, *8*, 14584, doi:10.1038/ncomms14584.

75. Boretto, M.; Cox, B.; Noben, M.; Hendriks, N.; Fassbender, A.; Roose, H.; Amant, F.; Timmerman, D.; Tomassetti, C.; Vanhie, A., et al. Development of organoids from mouse and human endometrium showing endometrial epithelium physiology and long-term expandability. *Development* **2017**, *144*, 1775-1786, doi:10.1242/dev.148478.

76. Fitzgerald, H.C.; Dhakal, P.; Behura, S.K.; Schust, D.J.; Spencer, T.E. Self-renewing endometrial epithelial organoids of the human uterus. *Proc Natl Acad Sci U S A* **2019**, *116*, 23132-23142, doi:10.1073/pnas.1915389116.

77. De Gregorio, V.; Imparato, G.; Urciuolo, F.; Tornesello, M.L.; Annunziata, C.; Buonaguro, F.M.; Netti, P.A. An Engineered Cell-Instructive Stroma for the Fabrication of a Novel Full Thickness Human Cervix Equivalent In Vitro. *Adv Healthc Mater* **2017**, *6*, doi:10.1002/adhm.201601199.

78. House, M.; Sanchez, C.C.; Rice, W.L.; Socrate, S.; Kaplan, D.L. Cervical tissue engineering using silk scaffolds and human cervical cells. *Tissue Eng Part A* **2010**, *16*, 2101-2112, doi:10.1089/ten.TEA.2009.0457.

79. Myers, K.M.; Socrate, S.; Paskaleva, A.; House, M. A study of the anisotropy and tension/compression behavior of human cervical tissue. *J Biomech Eng* **2010**, *132*, 021003, doi:10.1115/1.3197847.

80. Murphy, S.V.; Atala, A. 3D bioprinting of tissues and organs. *Nat Biotechnol* **2014**, *32*, 773-785, doi:10.1038/nbt.2958.

81. Rosso, F.; Giordano, A.; Barbarisi, M.; Barbarisi, A. From cell-ECM interactions to tissue engineering. *J Cell Physiol* **2004**, *199*, 174-180, doi:10.1002/jcp.10471.

82. Boretto, M.; Maenhoudt, N.; Luo, X.; Hennes, A.; Boeckx, B.; Bui, B.; Heremans, R.; Perneel, L.; Kobayashi, H.; Van Zundert, I., et al. Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening. *Nat Cell Biol* **2019**, *21*, 1041-1051, doi:10.1038/s41556-019-0360-z.

83. Kessler, M.; Hoffmann, K.; Brinkmann, V.; Thieck, O.; Jackisch, S.; Toelle, B.; Berger, H.; Mollenkopf, H.J.; Mangler, M.; Sehouli, J., et al. The Notch and Wnt pathways regulate stemness and differentiation in human fallopian tube organoids. *Nat Commun* **2015**, *6*, 8989, doi:10.1038/ncomms9989.

84. Zhang, X.Y.; Yanagi, Y.; Sheng, Z.; Nagata, K.; Nakayama, K.; Taguchi, T. Regeneration of diaphragm with bio-3D cellular patch. *Biomaterials* **2018**, *167*, 1-14, doi:10.1016/j.biomaterials.2018.03.012.